Key Takeaways CorMedix acquired Melinta for $300M, adding seven marketed therapies to its portfolio.The deal boosts 2025 revenue outlook to$325-$350M, with EPS accretion expected in 2026.Rezzayo offers near-term growth and is in phase III testing for expanded fungal infection use.CorMedix (CRMD) has taken a major step toward diversifying its revenue base and reducing reliance on a single product with the recent$300 million acquisition of Melinta Therapeutics. The move significantly expands the company’s m ...